On Jan. 7, 2021, Novavax announced that it had executed an Advance Purchase Agreement with the Commonwealth of Australia for 51 million doses of NVX-CoV2373, Novavax COVID-19 vaccine candidate.

This followed an agreement in principle that was announced in November 2020. NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax proprietary Matrix-M to enhance the immune response.